CNM-Au8 extended long-term survival and slowed disease progression in adults with early stage amyotrophic lateral sclerosis (ALS) compared with a placebo, according to final data from the RESCUE-ALS clinical trial and one-year findings in its open-label extension (OLE). Patients treated initially with CNM-Au8 in the main trial experienced…
CNM-Au8 slows disease progression and extends life, RESCUE-ALS finds
When I took my son to the doctor for his sports physical, the nurse went through a checklist of health history questions. The exchange took an unexpected turn when she asked about my husband’s health. “Is Dad healthy?” “No. He has ALS.” The nurse glanced at her computer screen.
The technology company Unlearn has joined with QurAlis to use artificial intelligence (AI) to speed up clinincal trials for amyotrophic lateral sclerosis (ALS). The aim of the collaboration is to minimize variability and increase the statistical strength of QurAlis’ clinical trials that are evaluating their primary ALS…
Arrowhead Pharmaceuticals has filed an application in Australia seeking the green light to launch the first clinical trial of ARO-SOD1, its RNA-based therapy for amyotrophic lateral sclerosis (ALS). The therapy is designed to reduce SOD1 protein levels in ALS patients carrying SOD1 mutations, which are estimated to account…
High blood levels of an omega-3 fatty acid is associated with a significantly slower disease progression and longer life among people with amyotrophic lateral sclerosis (ALS), a study reported. The link specifically was seen in people with elevated blood levels of an omega-3 fatty acid called alpha-linolenic acid…
Sometimes living with my ALS isn’t a matter of finding the right balance of effort and ease. At times, I have zero mental motivation to make the effort in the first place! And from the comments I read on many social media sites, other ALS patients have…
A new genetic risk score that takes hundreds of different genetic variations into account may help predict who’s most likely to develop amyotrophic lateral sclerosis (ALS). The score needs to be validated in future studies before being used in the clinic, but could be important to stratify people according…
Green Lake, in northern Michigan, is verdant and peaceful. Evergreen and aspen trees grow right to the water’s edge, and the shores are dotted with summer cottages and a smattering of small docks and boat houses. If I could conceive of the perfect lake, this would be it. My…
The French medtech company BrainTale has raised €4.5 million (about $4.9 million) to support the development of a noninvasive imaging analysis platform to help diagnose and monitor amyotrophic lateral sclerosis (ALS) and other neurological disorders. The platform, called BrainTale-care, is a digital medical platform that examines MRI scans…
My 13-year-old son and I started mountain biking a few summers ago during the pandemic. He quickly became a much more aggressive biker than me, tackling jumps and getting air while I try to keep my tires on the ground. He easily outpaces me, often waiting at trail…
Recent Posts
- ALS Network webinar series to continue in 2026 with expert speakers
- ALS nerve damage can occur without TDP-43 protein clumps: Study
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’